176 related articles for article (PubMed ID: 26143945)
1. AKT and cytosolic phospholipase A2α form a positive loop in prostate cancer cells.
Hua S; Vignarajan S; Yao M; Xie C; Sved P; Dong Q
Curr Cancer Drug Targets; 2015; 15(9):781-91. PubMed ID: 26143945
[TBL] [Abstract][Full Text] [Related]
2. Cytosolic phospholipase A2α sustains pAKT, pERK and AR levels in PTEN-null/mutated prostate cancer cells.
Hua S; Yao M; Vignarajan S; Witting P; Hejazi L; Gong Z; Teng Y; Niknami M; Assinder S; Richardson D; Dong Q
Biochim Biophys Acta; 2013 Jun; 1831(6):1146-57. PubMed ID: 23500889
[TBL] [Abstract][Full Text] [Related]
3. Loss of PTEN stabilizes the lipid modifying enzyme cytosolic phospholipase A₂α via AKT in prostate cancer cells.
Vignarajan S; Xie C; Yao M; Sun Y; Simanainen U; Sved P; Liu T; Dong Q
Oncotarget; 2014 Aug; 5(15):6289-99. PubMed ID: 25026288
[TBL] [Abstract][Full Text] [Related]
4. Cytosolic phospholipase A2α regulates G1 progression through modulating FOXO1 activity.
Naini SM; Choukroun GJ; Ryan JR; Hentschel DM; Shah JV; Bonventre JV
FASEB J; 2016 Mar; 30(3):1155-70. PubMed ID: 26644349
[TBL] [Abstract][Full Text] [Related]
5. Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation.
Bedolla R; Prihoda TJ; Kreisberg JI; Malik SN; Krishnegowda NK; Troyer DA; Ghosh PM
Clin Cancer Res; 2007 Jul; 13(13):3860-7. PubMed ID: 17606718
[TBL] [Abstract][Full Text] [Related]
6. cPLA2α mediates TGF-β-induced epithelial-mesenchymal transition in breast cancer through PI3k/Akt signaling.
Chen L; Fu H; Luo Y; Chen L; Cheng R; Zhang N; Guo H
Cell Death Dis; 2017 Apr; 8(4):e2728. PubMed ID: 28383549
[TBL] [Abstract][Full Text] [Related]
7. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
[TBL] [Abstract][Full Text] [Related]
8. Targeting of cytosolic phospholipase A2α impedes cell cycle re-entry of quiescent prostate cancer cells.
Yao M; Xie C; Kiang MY; Teng Y; Harman D; Tiffen J; Wang Q; Sved P; Bao S; Witting P; Holst J; Dong Q
Oncotarget; 2015 Oct; 6(33):34458-74. PubMed ID: 26416244
[TBL] [Abstract][Full Text] [Related]
9. Preferential chemosensitization of PTEN-mutated prostate cells by silencing the Akt kinase.
Priulla M; Calastretti A; Bruno P; Azzariti A; Paradiso A; Canti G; Nicolin A
Prostate; 2007 May; 67(7):782-9. PubMed ID: 17373720
[TBL] [Abstract][Full Text] [Related]
10. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
11. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
[TBL] [Abstract][Full Text] [Related]
12. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
[TBL] [Abstract][Full Text] [Related]
13. Cytosolic phospholipase A2α is critical for angiotensin II-induced hypertension and associated cardiovascular pathophysiology.
Khan NS; Song CY; Jennings BL; Estes AM; Fang XR; Bonventre JV; Malik KU
Hypertension; 2015 Apr; 65(4):784-92. PubMed ID: 25667212
[TBL] [Abstract][Full Text] [Related]
14. PTEN, more than the AKT pathway.
Blanco-Aparicio C; Renner O; Leal JF; Carnero A
Carcinogenesis; 2007 Jul; 28(7):1379-86. PubMed ID: 17341655
[TBL] [Abstract][Full Text] [Related]
15. Targeting cPLA2α inhibits gastric cancer and augments chemotherapy efficacy via suppressing Ras/MEK/ERK and Akt/β-catenin pathways.
Liao Y; Chen W; Shi W; Zha H
Cancer Chemother Pharmacol; 2021 Oct; 88(4):689-697. PubMed ID: 34255137
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of cytosolic phospholipase A2 alpha increases chemosensitivity in cervical carcinoma through suppressing β-catenin signaling.
Xu H; Sun Y; Zeng L; Li Y; Hu S; He S; Chen H; Zou Q; Luo B
Cancer Biol Ther; 2019; 20(6):912-921. PubMed ID: 30829552
[TBL] [Abstract][Full Text] [Related]
17. AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis.
Li N; Xue W; Yuan H; Dong B; Ding Y; Liu Y; Jiang M; Kan S; Sun T; Ren J; Pan Q; Li X; Zhang P; Hu G; Wang Y; Wang X; Li Q; Qin J
J Clin Invest; 2017 Apr; 127(4):1284-1302. PubMed ID: 28319045
[TBL] [Abstract][Full Text] [Related]
18. Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.
Shukla S; Maclennan GT; Hartman DJ; Fu P; Resnick MI; Gupta S
Int J Cancer; 2007 Oct; 121(7):1424-32. PubMed ID: 17551921
[TBL] [Abstract][Full Text] [Related]
19. Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis.
Tan M; Xu J; Siddiqui J; Feng F; Sun Y
Mol Cancer; 2016 Dec; 15(1):81. PubMed ID: 27955654
[TBL] [Abstract][Full Text] [Related]
20. Knockdown of Phospholipase Cε (PLCε) Inhibits Cell Proliferation via Phosphatase and Tensin Homolog Deleted on Chromosome 10 (PTEN)/AKT Signaling Pathway in Human Prostate Cancer.
Wang X; Fan Y; Du Z; Fan J; Hao Y; Wang J; Wu X; Luo C
Med Sci Monit; 2018 Jan; 24():254-263. PubMed ID: 29330357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
